The European Commission (EC) has approved an advance purchase agreement (APA) amendment for Valneva’s inactivated whole-virus Covid-19 vaccine, VLA2001.

The latest move follows remediation discussions based on the notice sent to the company regarding the termination of the initial APA for purchasing vaccine doses this year and the optional doses for next year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Valneva stated that the amendment would be signed following a mandatory period of five days.

During this time, the participating member states of the EU, including Denmark, Germany, Austria, Finland and Bulgaria, can choose to back off.

The amendment of the previous purchasing agreement will enable these member states to now buy 1.25 million VLA2001 doses this year, along with the option to buy an equivalent quantity later this year.

Valneva plans to deliver the first vaccine doses to the participating EU member states in the coming weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company aims to deploy nearly eight to ten million doses of remaining VLA2001 into the international markets.

Valneva CEO Thomas Lingelbach said: “We welcome the fact that the EC has decided not to terminate the APA, although we feel the order volume does not reflect the interest we see from European citizens.

“Despite this, we have decided to enter into this amendment to make our vaccine available to the Europeans who have been waiting for it.

“While the pandemic had been declining, the latest Covid-19 wave in Europe clearly underlines the need for alternative vaccines.”

The company is in discussions with many other countries globally regarding the potential additional supply and financing agreements.